This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2004 Sep 11;329(7466):581-2.

doi: 10.1136/bmj.329.7466.581.

Using monoamine oxidase type B inhibitors in Parkinson's disease

Yoav Ben-Shlomo, Kailash Bhatia

PMID: 15361418
PMCID: PMC516644
DOI: 10.1136/bmj.329.7466.581

Editorial

Using monoamine oxidase type B inhibitors in Parkinson's disease

Yoav Ben-Shlomo et al. BMJ. 2004.

. 2004 Sep 11;329(7466):581-2.

doi: 10.1136/bmj.329.7466.581.

Authors

Yoav Ben-Shlomo, Kailash Bhatia

PMID: 15361418
PMCID: PMC516644
DOI: 10.1136/bmj.329.7466.581

No abstract available

PubMed Disclaimer

Comment on

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.
Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, Gray R, Wheatley K. Ives NJ, et al. BMJ. 2004 Sep 11;329(7466):593. doi: 10.1136/bmj.38184.606169.AE. Epub 2004 Aug 13. BMJ. 2004. PMID: 15310558 Free PMC article.

Similar articles

Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C, Schumacher HC, Burgut FT. Henchcliffe C, et al. Expert Rev Neurother. 2005 Nov;5(6):811-21. doi: 10.1586/14737175.5.6.811. Expert Rev Neurother. 2005. PMID: 16274338 Review.
MAO-B inhibitors for the treatment of Parkinson's disease.
[No authors listed] [No authors listed] Mov Disord. 2002;17 Suppl 4:S38-44. doi: 10.1002/mds.5559. Mov Disord. 2002. PMID: 12211138 Review. No abstract available.
Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
Naoi M, Maruyama W. Naoi M, et al. Expert Rev Neurother. 2009 Aug;9(8):1233-50. doi: 10.1586/ern.09.68. Expert Rev Neurother. 2009. PMID: 19673610
Future therapies for Parkinson's disease.
Hauser RA, Lyons KE. Hauser RA, et al. Neurol Clin. 2004 Oct;22(3 Suppl):S149-66. doi: 10.1016/j.ncl.2004.05.005. Neurol Clin. 2004. PMID: 15501363 Review. No abstract available.
L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].
Ambrozi L, Birkmayer W, Riederer P, Youdim MB. Ambrozi L, et al. Br J Pharmacol. 1976 Nov;58(3):423P-424P. Br J Pharmacol. 1976. PMID: 791430 Free PMC article. Clinical Trial. No abstract available.

See all similar articles

Cited by

Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Lees A. Lees A. Drugs Aging. 2005;22(9):731-40. doi: 10.2165/00002512-200522090-00002. Drugs Aging. 2005. PMID: 16156677 Review.
NLRP3 inflammasome and glia maturation factor coordinately regulate neuroinflammation and neuronal loss in MPTP mouse model of Parkinson's disease.
Javed H, Thangavel R, Selvakumar GP, Dubova I, Schwartz N, Ahmed ME, Zaheer S, Kempuraj D, Iyer S, Zaheer A, Khan MM. Javed H, et al. Int Immunopharmacol. 2020 Jun;83:106441. doi: 10.1016/j.intimp.2020.106441. Epub 2020 Apr 4. Int Immunopharmacol. 2020. PMID: 32259702 Free PMC article.
Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
Ojha RP, Rastogi M, Devi BP, Agrawal A, Dubey GP. Ojha RP, et al. J Neuroimmune Pharmacol. 2012 Sep;7(3):609-18. doi: 10.1007/s11481-012-9363-2. Epub 2012 Apr 21. J Neuroimmune Pharmacol. 2012. PMID: 22527634

References

1. Lees AJ, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311: 1602-7. - PMC - PubMed
1. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. Monamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004;329: 593-6. - PMC - PubMed
1. Anonymous. MAO-B inhibitors for the treatment of Parkinson's disease. Movement Disord 2002;17(suppl 4): s38-s44. - PubMed
1. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359: 1589-98. - PubMed
1. Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360: 1037-43. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information